Price
$37.32-23.65%Social Signal Score
Analyst Ratings
39 analysts52-week range
- Last close
- $37.32
- Off 52w high
- -41.7%
- 200-day average
- $45.65
- vs 200-day
- -18.2%
Revenue
$78.49B+185.03%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Maziar Mike Doustdar
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 68,794
- Beta
- 0.35
- Country
- DK
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.64
Financials
Revenue
$78.49B+185.0%Net Income
$20.99B+114.1%EBITDA
$38.68B+194.0%Free Cash Flow
$42.40B+236.9%EPS (diluted)
$4.74+144.3%Shares Outstanding (diluted)
4.44B-12.4%Operating Expenses
$34.09BCash & Debt
$44.98BReturn of Capital
$3.50BDividend per Share
$0.58Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $309.06B | $102.43B | $23.06 |
| 2024 | $290.40B | $100.99B | $22.67 |
| 2023 | $232.26B | $83.68B | $18.67 |
| 2022 | $176.95B | $55.52B | $12.26 |
| 2021 | $140.80B | $47.76B | $10.40 |
| 2020 | $126.95B | $42.14B | $9.03 |
| 2019 | $122.02B | $38.95B | $8.21 |
| 2018 | $111.83B | $38.63B | $7.98 |
| 2017 | $111.70B | $38.13B | $7.71 |
| 2016 | $111.78B | $37.92B | $7.50 |
| 2015 | $107.93B | $34.86B | $6.78 |
| 2014 | $88.81B | $26.48B | $5.05 |
| 2013 | $83.57B | $25.18B | $4.70 |
| 2012 | $78.03B | $21.43B | $3.91 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NVO's reported EPS growth of 14.6% a year over 13 years.
- EPS in 5 years
- $45.52
- Implied price
- $637.30
- Return from $37.32
- 76.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $316.85 — today's price is already 88.2% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 10 | 12 | 14 | 16 | 18 |
|---|---|---|---|---|---|
| 4.6% | 50.5% | 56.1% | 61.0% | 65.4% | 69.3% |
| 9.6% | 57.7% | 63.6% | 68.7% | 73.3% | 77.4% |
| 14.6% | 64.9% | 71.0% | 76.4% | 81.2% | 85.5% |
| 19.6% | 72.1% | 78.5% | 84.1% | 89.1% | 93.6% |
| 24.6% | 79.3% | 86.0% | 91.8% | 97.0% | 101.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (82)
- Newszacks.com·20h ago·Neutral
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.
View source ↗ - Newsreuters.com·3d ago·Negative
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues The US FDA has extended its review of Novo Nordisk's experimental hemophilia A drug due to ongoing remediation work at a manufacturing facility, the Danish drugmaker said on Friday.
View source ↗ - Newsglobenewswire.com·3d ago·Negative
Novo provides update on the denecimig Biologics License Application (BLA) in the US Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA.
View source ↗ - Newsproactiveinvestors.com·4d ago·Negative
Eli Lilly obesity drug data adds pressure on Novo Nordisk Novo Nordisk (NYSE:NVO) faces further pressure in the obesity-drug market after Eli Lilly and Co (NYSE:LLY) reported promising mid-stage data for an experimental treatment that delivered greater weight loss than tirzepatide alone. EloraTZP, a combination of eloralintide and tirzepatide targeting amylin, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways, produced weight loss of up to 23.3% after 48 weeks in …
View source ↗ - Newszacks.com·5d ago·Neutral
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.
View source ↗ - Newszacks.com·5d ago·Negative
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines? NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.
View source ↗ - Newsreuters.com·6d ago·Negative
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study Patients who switched from weight-loss injections to Novo Nordisk's daily Wegovy pill continued to lose weight, according to data unveiled at a medical meeting on Wednesday, as the Danish drugmaker seeks to defend its lead over US rival Eli Lilly in the market for oral obesity treatments.
View source ↗ - Newscnbc.com·6d ago·Negative
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study People who switched from obesity injections to Novo's new Wegovy pill continued to lose weight after three months, according to an analysis of real-world data the company presented. Patients who switched from either a Wegovy shot or Lilly's Zepbound injection to the Wegovy pill and stayed on treatment for three months lost roughly 4% of their weight on average.
View source ↗ - Newsfool.com·6d ago·Neutral
Novo Nordisk Gives Uninspiring Outlook Investors were hopeful for a better growth estimate.
View source ↗ - Newszacks.com·6d ago·Neutral
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know Novo Nordisk (NVO) concluded the recent trading session at $38.31, signifying a -1.03% move from its prior day's close.
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Novo Nordisk: After A 70+% Drop, It's A Great Investment Novo Nordisk remains a compelling long-term investment despite a 70% share price decline amid GLP-1 competition. NVO's diversified portfolio, robust R&D pipeline, and rare disease milestones support improved 2026 guidance and international sales momentum. Free cash flow yield is set to rise as capex normalizes, with guidance for 7.6 billion USD FCF and a 4.6% dividend yield.
View source ↗ - Newsmarketwatch.com·7d ago·Positive
Novo Nordisk strikes second licensing deal since frosty capital-markets day Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
View source ↗ - Newsreuters.com·7d ago·Negative
China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug Jiangsu Hengrui Pharmaceuticals , China's largest drugmaker by market value, said on Tuesday it will license global rights to its weight-management drug HRS-1596 to Novo Nordisk A/S in a deal worth up to $2.6 billion.
View source ↗ - Newsfool.com·9d ago·Neutral
Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.
View source ↗ - Newsfool.com·10d ago·Negative
Could This Be Novo Nordisk's Next Billion-Dollar Weight-Loss Product? Novo Nordisk needs new products to better compete with Eli Lilly in the weight loss market. Zenagamtide is one of its promising candidates and could, eventually, generate over $1 billion in annual sales.
View source ↗ - Newszacks.com·10d ago·Neutral
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newscnbc.com·11d ago·Negative
Pharma stock soars 150% on injectables deal with Wegovy maker Novo The Swedish drug-delivery company agreed to license its PharmaShell technology to Novo Nordisk for up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditions. Novo Nordisk will use the technology to develop injectable drugs that could be administered monthly or quarterly, with Nanexa eligible for upfront and milestone payments as well as royalties on future sales.
View source ↗ - Newswsj.com·11d ago·Negative
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology Novo Nordisk agreed to license and develop the technology, which could cut the frequency patients need to inject its obesity and diabetes drugs.
View source ↗ - Newsreuters.com·11d ago·Negative
Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology Shares in Swedish drug-delivery company Nanexa more than doubled their value in early Friday trading after it signed a global licensing deal with Novo Nordisk worth up to about €1.17 billion ($1.33 billion).
View source ↗ - Newsseekingalpha.com·11d ago·Neutral
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine At its September 21 Capital Markets Day, Novo Nordisk A/S outlined plans to launch more than five multi-blockbusters by 2030 and deliver over DKK 150 billion in pipeline sales by 2035. CEO Maziar Doustdar said Novo will prioritize asset quality over deal size, with bolt-on acquisitions likely to be the focus while remaining open to larger deals. Meanwhile, in Q2, sales of the Wegovy pill were up 42.6% quarter-on-quarter to about DK
View source ↗ - Newscnbc.com·12d ago·Negative
Novo's new strategy hinges on something it can't manufacture: investor trust Novo set out ambitions to launch more than five potential multi-blockbuster drugs by 2030 on Monday, but shares fell 8%. Analysts said the update offered little new to restore confidence after the company's shares tumbled over the past two years.
View source ↗ - Newszacks.com·12d ago·Neutral
Novo Nordisk (NVO) Falls More Steeply Than Broader Market: What Investors Need to Know Novo Nordisk (NVO) closed the most recent trading day at $38.17, moving 3.12% from the previous trading session.
View source ↗ - Newsproactiveinvestors.com·12d ago·Negative
Novo Nordisk open to direct New York listing, CEO says Novo Nordisk (NYSE:NVO) (NYSE:NVO), the Danish drugmaker, would be open to considering a direct listing of its shares on the New York Stock Exchange, according to chief executive Mike Doustdar. Doustdar told the Financial Times that he could see advantages to such a move, although he clarified that the Danish pharmaceutical company is not currently exploring a change to its US listing structure.
View source ↗ - Newsreuters.com·13d ago·Negative
Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT Novo Nordisk is open to the idea of upgrading its New York listing as part of efforts to raise the Danish weight-loss drugmaker's profile in the country, its chief executive told Financial Times in an interview published on Wednesday.
View source ↗ - Newsreuters.com·13d ago·Negative
Novo CEO says pills could capture 50% of weight-loss market by 2030 Weight-loss pills could capture as much as half of the global obesity drug market by 2030, Novo Nordisk's chief executive told Reuters on Tuesday, as the Danish drugmaker positions itself for a shift away from weekly injections.
View source ↗ - Newsreuters.com·14d ago·Negative
Novo Nordisk and UNICEF renew push to prevent childhood obesity Novo Nordisk and UNICEF have expanded their partnership to help prevent childhood overweight and obesity, the Danish drugmaker said on Tuesday.
View source ↗ - Newscnbc.com·14d ago·Negative
Novo CEO signals M&A opportunities to strengthen drug pipeline Novo CEO Mike Doustdar told CNBC it's mulling M&A opportunities amid increasing competition. In this article NVO
View source ↗ - Newsyoutube.com·14d ago·Neutral
Monday's Final Takeaways: NVO Stumbles in GLP-1 Race, U.S.-China Summit Begins Eli Lilly (LLY) is gaining speed in capturing the GLP-1 craze as Novo (NVO) continues to struggle in catching a bullish bid. Meanwhile, the U.S.-China summit begins with President Trump and China President Xi Jinping poised to meet on Thursday.
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
Novo Resources Releases Updated Corporate Presentation PERTH, Australia, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its updated corporate presentation, now available on the Company's website.
View source ↗ - Newsmarketbeat.com·14d ago·Positive
Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction Novo Nordisk A/S NYSE: NVO outlined an updated strategy at its Capital Markets Day centered on diabetes and obesity, expansion into blood and endocrine disorders, liver disease and cardiovascular conditions, and a growing focus on consumer-facing prescription medicine channels.
View source ↗ - Newsproactiveinvestors.com·14d ago·Negative
Novo Nordisk shares plunge over 7% as new targets fail to reassure investors Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by 2030 and generate more than 150 billion Danish kroner (US$23 billion) in risk-adjusted pipeline sales by 2035, including current p…
View source ↗ - Newszacks.com·14d ago·Positive
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU NVO's Sogroya wins a positive CHMP opinion for idiopathic short stature in the EU, potentially broadening its pediatric growth disorder reach.
View source ↗ - Newsschaeffersresearch.com·14d ago·Negative
Novo Shares Slip as Growth Plan Disappoints Investors Novo Nordisk (NYSE:NVO) shares are down 6.2% to trade at $40.55, after investors came away unimpressed about the drugmaker's pipeline amid increasingly crowded competition in the weight loss market.
View source ↗ - Newsbenzinga.com·14d ago·Neutral
Beyond Ozempic: Novo Nordisk Plots Next Decade Growth with Bigger Pipeline, Slimmer Workforce Novo Nordisk A/S (NYSE:NVO) on Monday outlined a broad strategic roadmap targeting sustained global expansion during its Capital Markets Day 2026 presentation.
View source ↗ - Newsbenzinga.com·15d ago·Neutral
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 1% on Monday.
View source ↗ - Newsreuters.com·15d ago·Negative
Novo says its next-gen obesity drug tops Lilly rival in late-stage study Novo Nordisk said on Monday its next-generation experimental drug had achieved an estimated average weight loss of 12.4% in a late-stage trial and that it was superior to Eli Lilly's drug.
View source ↗ - Newsreuters.com·15d ago·Negative
Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says Novo Nordisk aims to launch more than five blockbuster drugs by 2030 and to deliver more than 150 billion Danish crowns ($23 billion) in pipeline sales in 2035, its CEO Mike Doustdar said at its Capital Markets Day in London.
View source ↗ - Newswsj.com·15d ago·Negative
Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years Shares in Novo Nordisk fell more than 4% as its CEO laid out plans to launch new blockbuster drugs in the next few years while expanding into further treatment areas.
View source ↗ - Newswsj.com·15d ago·Negative
Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years — Update Shares in Novo Nordisk fell more than 4% as its CEO laid out plans to launch new blockbuster drugs in the next few years while expanding into further treatment areas.
View source ↗ - Newsmarketwatch.com·15d ago·Negative
Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals Novo Nordisk stock tumbled on Monday as the weight-loss drug manufacturer failed to excite investors hoping for a turnaround.
View source ↗ - Newscnbc.com·15d ago·Negative
Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
View source ↗ - Newsreuters.com·15d ago·Negative
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs Wegovy-maker Novo Nordisk's CEO Mike Doustdar will face pressure on Monday to set out his strategy for competing with US rival Eli Lilly and how he plans to boost the company's growth beyond the blockbuster weight-loss drug.
View source ↗ - Newszacks.com·17d ago·Neutral
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union NVO's denecimig wins a positive European opinion for hemophilia A, with flexible dosing and a potential 2026 launch.
View source ↗ - Newszacks.com·18d ago·Negative
Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery NVO is expanding its AI strategy with Anthropic to tackle drug discovery challenges, boost R&D productivity and develop new medicines faster.
View source ↗ - Newszacks.com·18d ago·Positive
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now? NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.
View source ↗ - Newsreuters.com·19d ago·Negative
Novo, Orbis sign up to $1.4 billion deal to develop oral drugs Orbis Medicines said on Thursday it had signed a drug discovery and licensing deal with Novo Nordisk worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases that are traditionally treated with injectable drugs.
View source ↗ - Newszacks.com·19d ago·Neutral
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note Novo Nordisk (NVO) closed the most recent trading day at $41.67, moving 2.02% from the previous trading session.
View source ↗ - Newsbarrons.com·19d ago·Negative
Will AI Save the Pharma Industry Billions? Novo's Anthropic Deal Is Betting on It. Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.
View source ↗ - Newszacks.com·21d ago·Negative
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes? Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
View source ↗ - Newszacks.com·21d ago·Neutral
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newsreuters.com·21d ago·Negative
Novo Nordisk rebrands as 'Novo', announces cultural reset Novo Nordisk is changing its day-to-day name to 'Novo', and taking a new approach to company culture as it looks to claw back ground in the fierce obesity drug race, the Danish drugmaker said on Monday.
View source ↗ - Newswsj.com·22d ago·Negative
Novo Nordisk to Rebrand as Novo The drugmaker said its new name aims to make it more recognizable to compete in the market for obesity medications.
View source ↗ - Newscnbc.com·22d ago·Negative
Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share Novo Nordisk said it is rebranding its name to "Novo" and updating its corporate culture, as the company works to win back market share in the obesity drug space. The Danish drugmaker called the changes the beginning of a new chapter, as it faces stiff competition from Eli Lilly and investor pressure to deliver new blockbuster products.
View source ↗ - Newsfool.com·22d ago·Neutral
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst Novo Nordisk launched its Wegovy pill in early 2026, with Eli Lilly quickly following with a pill called Foundayo. Novo Nordisk's pill has been very well received, while Eli Lilly's pill has been slower to gain traction.
View source ↗ - Newszacks.com·25d ago·Neutral
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights Novo Nordisk (NVO) closed the most recent trading day at $44.01, moving 1.23% from the previous trading session.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Novo Nordisk: Valuation Reflects High Risk, But Solid Margin Of Safety Novo Nordisk remains a Strong Buy after a robust Q2, with another guidance boost and strong free cash flow growth. NVO's valuation reflects high risk, yet intrinsic value estimates suggest a significant discount to current market price. GLP-1 market leadership persists, but competitive and regulatory pressures, plus post-LOE strategy execution, are critical forward risks.
View source ↗ - Newsreuters.com·26d ago·Negative
Novo Nordisk says Wegovy approved in China for liver disease MASH Denmark's Novo Nordisk said on Thursday its blockbuster weight-loss drug Wegovy had been approved in China as the first GLP-1 RA class of drugs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
View source ↗ - Newsyoutube.com·28d ago·Negative
Ozempic maker: We sold health when people wanted weight loss Novo Nordisk invented the GLP-1 category, told the world that weight loss was the least important thing its drugs did, and then watched a competitor take market share by promising a bigger number. Mike Doustdar became president and CEO of Novo Nordisk in August 2025, after 34 years at the company that began with a summer job making photocopies in its Vienna office.
View source ↗ - Newsreuters.com·29d ago·Negative
Novo scraps two more heart drug trials, further dimming growth beyond obesity Novo Nordisk said on Monday it had halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's efforts to diversify beyond its blockbuster obesity and diabetes franchise.
View source ↗ - Newswsj.com·29d ago·Negative
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial The Danish drugmaker said the clinical trial met its primary goal after 68 weeks of treatment.
View source ↗ - Newsreuters.com·29d ago·Negative
Novo Nordisk says semaglutide cut obesity rates in young children in trial Novo Nordisk said on Monday that in a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide, the active ingredient in its blockbuster weight-loss drug Wegovy, were no longer classified as having obesity after 68 weeks, assuming full adherence to the treatment.
View source ↗ - Newsreuters.com·35d ago·Negative
Novo Nordisk launches Wegovy weight-loss pill in Germany Novo Nordisk has launched its Wegovy pill in Germany, a spokesperson for the Danish drugmaker said on Tuesday, with investors keenly focused on the oral weight-loss treatment in light of intensifying competition with U.S. rival Eli Lilly.
View source ↗ - Newsfool.com·37d ago·Neutral
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly? Novo Nordisk was first with a GLP-1 weight-loss shot, but lost the lead to Eli Lilly. Novo Nordisk was first to market with a GLP-1 pill, though Eli Lilly is now competing there, as well.
View source ↗ - Newsinvezz.com·39d ago·Negative
Novo Nordisk stock falls as Deutsche Bank downgrades shares to sell Novo Nordisk shares fell on Thursday after Deutsche Bank downgraded the Danish drugmaker to Sell from Hold and lowered its price target, citing concerns over the company's growth prospects. The company's US shares declined about 2% in trading, with Deutsche Bank cutting its target to 265 Danish kroner from 290 kroner.
View source ↗ - Newswsj.com·39d ago·Negative
Novo Nordisk Shares Drop as Bank Downgrade Reflects Growth Concerns The stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes and Wegovy weight-loss jabs.
View source ↗ - Newsmarketwatch.com·40d ago·Negative
Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.
View source ↗ - Newsreuters.com·40d ago·Negative
China drug regulator accepts Novo Nordisk's application for oral Wegovy China's drug regulator has accepted Novo Nordisk's marketing application for the oral version of its weight-loss drug Wegovy, the Danish drugmaker said in a statement on Thursday.
View source ↗ - Newszacks.com·40d ago·Positive
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now? Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.
View source ↗ - News247wallst.com·41d ago·Negative
Eli Lilly vs Novo Nordisk: One Winner in The Weight-Loss Drug Gold Rush Eli Lilly (NYSE:LLY | LLY Price Prediction) and Novo Nordisk (NYSE:NVO) both reported Q2 2026 results in early August, and the split screen was jarring.
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
Novo Resources Releases Updated Corporate Presentation PERTH, Western Australia, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its updated corporate presentation, now available on the Company's website.
View source ↗ - Newsseekingalpha.com·43d ago·Neutral
… Buying Opportunity Novo Nordisk stock appears to have formed a long-term bottom, with its turnaround gaining traction as market share losses to Eli Lilly stabilize. NVO trades at just over 15x forward earnings, half LLY's multiple, with downside risk now materially reduced given improved guidance and resilient profitability. Despite steep pricing pressures and lower gross margins, NVO's weight loss franchise remains highly profitable, and the recent Wegovy pill's performance boosts confidence.
View source ↗ - Newsreuters.com·47d ago·Negative
Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump Celon Pharma's experimental semaglutide product Reduzek, a generic alternative to Novo Nordisk's Wegovy and Ozempic, matched the blockbuster weight-loss drugs in an early-stage bioequivalence study, the Polish drugmaker said on Thursday.
View source ↗ - Newsseekingalpha.com·47d ago·Positive
Novo Nordisk: The Best Value In Pharma Novo Nordisk A/S remains a Strong Buy, trading at just 12.5x P/E despite robust growth and global expansion beyond the US market. Novo Nordisk's international operations now drive 65% of group growth, with EUCAN obesity care up 52% at CER and the oral franchise outpacing competitors. US list price cuts in 2027 are misunderstood; realized net pricing and structural liabilities will shift, but net revenues are unlikely to halve.
View source ↗ - News247wallst.com·47d ago·Neutral
Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold? Among the pharma names investors debate most, Eli Lilly (NYSE:LLY | LLY Price Prediction) at $1,216.46 screens most constructively, Novo Nordisk (NYSE:NVO) at $45.92 looks range-bound, and Merck (NYSE:MRK) at $135.97 screens as fairly valued.
View source ↗ - Newswsj.com·48d ago·Neutral
Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills The study will run into 2028, testing two low doses of Wegovy, and follows the company disclosing recently that uptake of the pill had been particularly strong for its lowest doses across self-paying patients.
View source ↗ - Newsreuters.com·48d ago·Negative
Novo begins study to find lowest effective dose for Wegovy pill Danish drugmaker Novo Nordisk is testing lower doses of its Wegovy pill in a new late-stage study to find the lowest dose that still helps patients lose weight, according to a U.S. government database of clinical trials.
View source ↗ - Newsyoutube.com·54d ago·Negative
Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer Novo Nordisk President and CEO Mike Doustdar joins 'Mad Money' host Jim Cramer to talk quarterly results, launching its GLP-1 pill, competition in the weight-loss drug space, and more.
View source ↗ - Newsfoxbusiness.com·54d ago·Neutral
Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America Novo Nordisk CEO argues weight loss drugs could slash health care costs and boost productivity as GLP-1 adoption remains in its early innings.
View source ↗ - Newszacks.com·54d ago·Positive
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock? NVO faces near-term pressure from flat Wegovy sales, pricing challenges and pipeline setbacks, but its broad cardiometabolic pipeline offers long-term potential.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
The Market Is (Still) Underestimating Novo Nordisk Novo Nordisk remains a Buy, underpinned by strong long-term fundamentals and a promising lead in obesity care, especially with the Wegovy pill. Despite near-term challenges—declining gross margins, high CapEx, and a failed ziltivekimab trial—Novo Nordisk's operating margins and capital allocation remain robust. Management raised 2026 guidance, now expecting adjusted sales and operating profit to decline up to 6%, a significant improvement from p
View source ↗ - Newsfool.com·55d ago·Neutral
Novo Nordisk Stock: Buy or Sell? Novo Nordisk (NVO -1.17%) is more than just a weight loss company.
View source ↗ - Newsmarketbeat.com·58d ago·Neutral
Novo Nordisk A/S Q2 Earnings Call Highlights Novo Nordisk A/S NYSE: NVO reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.75 per share
Typical surprise +11.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.96 vs $0.82beat
- Wed, May 6$1.04 vs $0.87beat
- Tue, Feb 3$1.00 vs $0.90beat
- Wed, Nov 5$1.02 vs $0.77beat
- Wed, Aug 6$0.97 vs $0.93beat
- Wed, May 7$0.92 vs $0.92beat
Estimates and results for NVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (28d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (18d later)Sell$1,001 - $15,000
- Scott Mr Franklinhouse · FL18 · disclosed Sep 18, 2026 (23d later)Buy$1,001 - $15,000
- Scott Franklinhouse · FL18 · disclosed Sep 18, 2026 (23d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$15,001 - $50,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (41d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Oct 21, 2025 (6d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (42d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Sep 1, 2025 (4d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Aug 21, 2025 (2d later)Buy$15,001 - $50,000
- Scott Franklinhouse · FL18 · disclosed Aug 15, 2025 (11d later)Buy$1,001 - $15,000
- Scott Franklinhouse · FL18 · disclosed Aug 15, 2025 (11d later)Buy$15,001 - $50,000
- Scott Franklinhouse · FL18 · disclosed Aug 15, 2025 (11d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (34d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (65d later)Buy$1,001 - $15,000
- Laurel Leehouse · FL15 · disclosed Jun 23, 2025 (46d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.